| Company Name: |
BOC Sciences |
| Tel: |
1-631-485-4226; 16314854226 |
| Email: |
info@bocsci.com |
MKC-1 manufacturers
- MKC-1
-
- $52.00
-
2026-07-27
- CAS:125313-92-0
- Purity: 99.85%
- Supply Ability: 10g
|
| Product Name: | MKC-1 | | Synonyms: | MKC-1;Ro 31-7453;3-(1-Methylindol-3-yl)-4-(1-Methyl-6-nitroindol-3-yl)pyrrole-2,5-dione;3-(1-Methyl-1H-indol-3-yl)-4-(1-methyl-6-nitro-1H-indol-3-yl)-1H-pyrrole-2,5-dione;1H-Pyrrole-2,5-dione, 3-(1-methyl-1H-indol-3-yl)-4-(1-methyl-6-nitro-1H-indol-3-yl)-;inhibit,mTOR,Apoptosis,Protein kinase B,PKB,MKC 1,renal cell cancer,Caki-1,Mammalian target of Rapamycin,orally active,Microtubule/Tubulin,MKC-1,Akt,pancreatic cancer,Inhibitor,MKC1;3-(1-Methyl-1H-indol-3-yl)-4-(1-methyl-6-nitro-1H-indol-3-yl)-1H-pyrrole-2,5-dione , MKC-1;MKC-1, 10 mM in DMSO | | CAS: | 125313-92-0 | | MF: | C22H16N4O4 | | MW: | 400.39 | | EINECS: | | | Product Categories: | | | Mol File: | 125313-92-0.mol |  |
| | MKC-1 Chemical Properties |
| Melting point | 173-174 °C | | Boiling point | 714.5±60.0 °C(Predicted) | | density | 1.49±0.1 g/cm3(Predicted) | | storage temp. | Store at -20°C | | form | Solid | | pka | 7.71±0.60(Predicted) | | color | Orange to red |
| | MKC-1 Usage And Synthesis |
| Uses | MKC-1 (Ro-31-7453) is an orally active and potent cell cycle inhibitor with broad antitumor activity. MKC-1 inhibits the Akt/mTOR pathway. MKC-1 arrests cellular mitosis and induces cell apoptosis by binding to a number of different cellular proteins including tubulin and members of the importin β family[1][2][3]. | | in vivo | MKC-1 (200 mg/kg, orally, daily) significantly increased the median survival time (MST) of mice bearing Caki-1 renal cell xenograft tumors[3]. | | References | [1] Wang M, et al. The first design and synthesis of [11C]MKC-1 ([11C]Ro 31-7453), a new potential PET cancer imaging agent. Nucl Med Biol. 2010 Oct;37(7):763-75. DOI:10.1016/j.nucmedbio.2010.04.186
[2] Faris JE, et al. A phase 2 study of oral MKC-1, an inhibitor of importin-β, tubulin, and the mTOR pathway in patients with unresectable or metastatic pancreatic cancer. Invest New Drugs. 2012 Aug;30(4):1614-20. DOI:10.1007/s10637-011-9708-3
[3] Burke P, et al. MKC-1 significantly increases survival of mice bearing renal cell carcinoma Caki-1 xenograft tumors through inhibition of the Akt/mTOR pathway[J]. Molecular Cancer Therapeutics, 2007(12):3524S-3525S. |
| | MKC-1 Preparation Products And Raw materials |
|